Brief: AngioDynamics Cuts Fiscal Year 2023 Guidance

AngioDynamics

30/03/2023 12:15

Mar 30 (Reuters) - AngioDynamics Outlook FY sales USD 338-342 million.
* Q3 adjusted EBITDA USD 4.3 million
* Q3 net income USD -9.5 million
* Q3 adjusted EPS USD -0.03
* Q3 gross margin 50.2%
* Q3 adjusted net income USD -1 million
* Q3 sales USD 80.7 million
* Outlook FY adjusted EPS USD -0.06 to -0.01
* Outlook FY gross margin 51-52%